Compositions for the treatment or prevention of drug-resistant tumours

Overview

HKBU has developed compositions for the treatment or prevention of drug-resistant tumors, particularly those resistant to BRAF V600E inhibitors. This invention focuses on a combination of oxymatrine and artesunate, which exhibits synergistic effects in inhibiting tumor growth, especially melanoma resistant to BRAF V600E inhibitors, while being safe for normal cells.

  • Compositions for the treatment or prevention of drug-resistant tumours 0
Commercialisation opportunities
Non-exclusive licensing
Problem addressed

This invention addresses the problem of drug resistance in tumors, specifically those resistant to BRAF V600E inhibitors (e.g., vemurafenib, dabrafenib).

Innovation
  • The current invention uses the combination of oxymatrine and artesunate demonstrates a synergistic effect in inhibiting tumor growth, particularly in melanoma resistant to BRAF V600E inhibitors. 
Key impact
  • Maintain safety for normal cells
  • Overcomes Drug Resistance: Targets tumors resistant to BRAF V600E inhibitors (e.g., vemurafenib, dabrafenib) and even MEK inhibitor combinations.
Application
  • The pharmaceutical composition can be administered in various forms, including tablets, capsules, injections, and oral liquids.

Patent

  • China Patent Publication No.: CN 118340776 A
Hong Kong Baptist University (HKBU)

Aspiring to be a leading, research-led, liberal arts University in Asia, Hong Kong Baptist University is committed to conducting world-leading investigations that extends the frontiers of knowledge, tackles global challenges and benefits the community at home and abroad. 

Pursuing research excellence is one of the priorities of the University’s Institutional Strategic Plan 2018-2028. The University keeps enhancing its capacity and strength to produce world-class research with an aim to bring significant impact to the society. 

Enquiry
Related Innovations